Life is unpredictable and can change in a moment. The hectic pace of life, work and the lack of activity due to the pandemic are affecting our heart health.
Being aware of the signs, paying attention to any atypical symptoms, even minimal ones, or those of our loved ones, and listening to our body are all important to preserve our heart’s health.
Early diagnosis opens the door to more effective treatment and care. Bernard Colombo's story is all too common: despite his expertise in the subject matter, he missed the early signs of a heart attack two years ago, narrowly avoiding a serious outcome. This film highlights the importance of patient education and the value of rapid testing solutions to dramatically improve the prognosis and outcomes for sufferers of sudden cardiac events.
Each year, 1 of out 12 Canadians over 20 is diagnosed with cardiac disease and 100 000 over 40 are diagnosed with heart failure, this incurable condition, adding up to the 750 000 ones already living with it1.
Clinical Assessment, plus NT-proBNP testing, helps physicians to make better decisions in heart failure management at every stage of care.
Although the risk of stroke can be reduced by 64% with anticoagulants4, 50% of patients don’t receive this treatment due to concern about bleeding5. In 2016, the ABC bleeding score was introduced, outperforming all previous scoring methods5. ABC stands for Age, Biomarker, Clinical bleeding history. The biomarkers examined are haemoglobin, TnT hs and GDF-15 (Growth-Differentiation factor-15), which is considered the strongest predictor of bleeding risk5.
Roche invests in R&D for more predictive assays that will ensure better patient outcomes in the near future!
Learn more on medical innovations treat cardiovascular and metabolism diseases such as heart attacks and diabetes:
Ponikowski et al. (2016). Euro Heart j » 37(27), 2129-200
Januzzi et al. (2006) Euro Heart j. 27, 330-337
Hart RG, et al. Ann intern Med 2007; 146:857-867.
Hijazi Z, et al. Lancet 2016; 387:2302-2311
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
You are now leaving the website of Hoffmann-La Roche Ltd. ("Roche Canada"). Links to all external sites are provided as a resource to our visitors. Roche Canada assumes no responsibility for the content of these sites. Roche Canada has no control over these sites and the opinions, claims or comments contained in these sites should not be attributed to Roche Canada, unless otherwise specified.